Condensed Consolidated Statements of Cash Flows $ in Thousands, € in Millions	3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Sep. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Cash flows from operating activities:
Net income	$ 11,694	$ 9,739	$ 19,540	$ 4,858	$ 33,316	$ 33,327
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization					8,446	9,137
Loss (gain) on disposal of property, plant & equipment					108	(6,206)
Gain on sale of Molded Fiber business	0		(15,623)		0	(15,623)
Share-based compensation					3,450	2,370
Deferred income taxes					474	415
Change in fair value of contingent consideration	238		3,346		3,289	9,348
Changes in operating assets and liabilities:
Receivables, net					(5,791)	(19,841)
Inventories					(16,267)	(20,085)
Prepaid expenses and other current assets					377	118
Income taxes payable					(2,161)	(3,624)
Other assets					1,255	(2,637)
Accounts payable					6,715	6,334
Accrued expenses					(4,272)	12,991
Deferred revenue					(865)	501
Non-qualified deferred compensation plan and other liabilities					559	(6,669)
Net cash provided by (used in) operating activities					28,633	(144)
Cash flows from investing activities:
Additions to property, plant, and equipment					(7,734)	(10,816)
Proceeds from sale of Molded Fiber					0	29,007
Proceeds from sale of fixed assets					2	6,717
Net cash (used in) provided by investing activities					(7,732)	4,255
Cash flows from financing activities:
Proceeds from advances on revolving line of credit					9,000	44,000
Payments on revolving line of credit					(18,000)	(45,000)
Principal payments of long-term debt					(3,000)	(3,000)
Payment of contingent consideration					(5,000)	0
Principal payments on finance lease obligations					(47)	(47)
Proceeds from exercise of stock options					680	178
Payment of statutory withholdings for restricted stock units vested					(2,413)	(1,302)
Net cash used in financing activities					(18,780)	(5,171)
Effect of foreign currency exchange rates on cash and cash equivalents					(196)	(120)
Net increase (decrease) in cash and cash equivalents					1,925	(1,180)
Cash and cash equivalents at beginning of period		$ 4,451		$ 11,117	4,451	11,117	$ 11,117
Cash and cash equivalents at end of period	$ 6,376		$ 9,937		6,376	9,937	$ 4,451
Advant Medical [Member]
Cash flows from investing activities:
Acquisition, net of cash acquired					0	(20,768)
DAS Medical [Member]
Cash flows from investing activities:
Acquisition, net of cash acquired					$ 0	$ 115